Add BrightSurf on Google Email

Dartmouth Health


Dartmouth Health researchers identify additional risk for patients with tick-borne alpha-gal syndrome apart from meat allergy

Researchers at Dartmouth Health identified a higher risk of severe reactions in patients with alpha-gal syndrome when receiving blood plasma or platelet transfusions, particularly from type O donors. The study suggests that pre-existing antibodies to alpha-gal from tick bites may be a contributing factor.

SourceDartmouth Health·JournalJAMA Internal Medicine·TypeRandomized controlled/clinical trial·DateAug 24, 2026

New study pinpoints barriers to timely head and neck cancer treatment in rural areas

A new study led by Dartmouth Cancer Center identifies key barriers to timely head and neck cancer treatment in rural areas, including transportation and caregiver challenges. The research highlights the importance of dedicated staff, strong community ties, and peer support in navigating the complexity of cancer care.

SourceDartmouth Health·JournalJAMA Otolaryngology–Head & Neck Surgery·TypeSurvey·DateApr 16, 2026

New study finds common blood pressure drug boosts cancer treatment

A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.

SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 25, 2026

Estrogen and PARP inhibitor combination for advanced ER+ breast cancer shows promise in preclinical models

A new study by researchers at Dartmouth Cancer Center shows that a combination of estrogen and PARP inhibitors can effectively treat advanced ER+ breast cancer by damaging cancer cells and preventing DNA repair. The treatment strategy has been shown to be effective regardless of BRCA1 or BRCA2 genetic mutations.

SourceDartmouth Health·JournalClinical Cancer Research·TypeExperimental study·DateJul 13, 2023

Alternating estrogen and anti-estrogen therapies is effective in treating metastatic breast cancer

Researchers at Dartmouth Cancer Center found that alternating estrogen stimulation and anti-estrogen therapy is an effective treatment for patients with metastatic or advanced ER+ breast cancer. The POLLY trial showed that 42% of patients experienced tumor stabilization, while no patients discontinued treatment due to side effects.

SourceDartmouth Health·JournalClinical Cancer Research·TypeRandomized controlled/clinical trial·DateMay 15, 2023

New Hampshire and Northeast U.S. region’s high childhood cancer rates re-examined

A new study from Dartmouth Cancer Center re-examines claims of high pediatric cancer rates in New Hampshire, revealing the Northeast region has a statistically significantly higher incidence of cancer compared to all other U.S. regions. Within the Northeastern states, no single state is an outlier, with significant variations in incide...

SourceDartmouth Health·JournalCancer Epidemiology Biomarkers & Prevention·TypeLiterature review·DateJul 21, 2022

Improving serious illness communication for patients with advanced cancer

A quality improvement project at Dartmouth Cancer Center increased serious illness conversations between patients and providers from 0% to 70%, reflecting the importance of early discussions on prognosis and treatment options. The project's success was attributed to standardized work, an engaged interdisciplinary team, and system-level...

SourceDartmouth Health·JournalJCO Oncology Practice·TypeRandomized controlled/clinical trial·DateJul 20, 2022

New study examining women’s breast density knowledge suggests opportunities for improvement

A new study suggests that while breast density knowledge may be increasing due to existing state laws, there is still room for improvement. The study found that most women with non-dense breasts did not correctly know their own density, and that lower education was associated with a lower chance of accurately knowing one's own density.

SourceDartmouth Health·JournalJournal of the American College of Radiology·TypeSurvey·DateApr 25, 2022

Treating deadly mammary cancer with a novel plant virus-based immunotherapy

A new study reveals that intra-tumoral injections of a plant virus-based immunotherapy could lead to groundbreaking therapy for both canine and human inflammatory breast cancer patients. The treatment generated potent local and systemic anti-tumor immune responses, improving quality of life and survival in treated dogs.

SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 14, 2022

New detailed immune-profiling method uses only DNA from blood

A novel immune-profiling method can return detailed immune cell type proportions using only DNA from blood, potentially allowing for individualized prediction of outcomes in immunotherapy patients. This approach offers the opportunity to ask and answer questions about the immune system in health and disease.

SourceDartmouth Health·JournalNature Communications·TypeExperimental study·DateFeb 9, 2022

AI that classifies colorectal polyps proves useful in the clinic

A new AI model has been developed to classify colorectal polyps, demonstrating accuracy and sensitivity at a level comparable to practicing pathologists. The model was tested in a clinical trial involving 15 pathologists, showing significant improvements in accuracy compared to traditional methods.

SourceDartmouth Health·JournalJAMA Network Open·TypeComputational simulation/modeling·DateNov 18, 2021

Targeting drug-resistant breast cancer with estrogen

Researchers at Dartmouth's Norris Cotton Cancer Center have found that cycling between estrogen treatment and anti-estrogen therapies can dramatically increase the duration of tumor regression in mice. This unconventional approach suggests treating short-term with estrogen before resistance occurs, leading to better long-term control.

SourceDartmouth Health·JournalOncogene·DateApr 23, 2021

Rural Hondurans embrace cancer screening opportunities

A collaborative research team from Dartmouth and Honduras found a high level of participation in rural cancer screening events, resulting in over 88% of identified individuals seeking follow-up care. The 'multiphasic' approach involved multiple cancer screenings in one event, which was well-received by local communities.

SourceDartmouth Health·JournalJCO Global Oncology·DateMar 11, 2020

New mechanism may safely prevent and reverse obesity

Blocking a cellular receptor called AHR prevents and reverses obesity in mice by inhibiting key genes involved in fat metabolism. Researchers at Dartmouth's Norris Cotton Cancer Center found that the drug NF, which blocks AHR, can not only prevent but also reverse obesity in study mice.

SourceDartmouth Health·JournalInternational Journal of Obesity·DateJan 13, 2020